Recent

% | $
Quotes you view appear here for quick access.

STAAR Surgical Company Message Board

you are viewing a single comment's thread.

view the rest of the posts
  • galaberge galaberge Jan 17, 2012 12:21 PM Flag

    2012 will have $75-80M revenue

    Before saying stu..dities you should check these links.

    After, you may comment on an intelligent manner….


    http://www.staar.com/html/consumer.html
    The Visian Toric ICL™ – Implantable Collamer lenses for treatment of myopia with astigmatism during refractive surgery. (Please note the Visian TICL is available internationally only, but is currently under review by the U.S. FDA)

    http://www.osnsupersite.com/view.aspx?rid=91416
    WAILEA, Hawaii — The slow path to approval by the U.S. Food and Drug Administration that new products face is threatening to push the market, which is already two generations behind in some technologies, even further back, a speaker said here.
    In some cases, global companies are creating marketing strategies that simply ignore the U.S. market, John A. Vukich, MD, said at Hawaiian Eye 2012.
    "We do have excellent technology," Dr. Vukich said, "but I think we risk losing the edge in innovation that the U.S. is known for."
    Toric multifocal lenses top the long list of products ophthalmologists would like to see in the U.S. market, he said. In addition, numerous other products and designs that have been available outside the United States for years have sat before the FDA for almost as long with no forward movement.
    Dr. Vukich urged ophthalmologists to work together to end the regulatory roadblock.
    "Individually and as a group we need to advocate for reform of the regulatory process," he said. "I'm not suggesting that any of the these devices that I've just shown are the answer, but I think most of us would love to have the opportunity to decide for ourselves and offer our patients what we believe is the latest in technology."

    Strong STAA

 
STAA
6.28+0.04(+0.64%)Feb 12 4:00 PMEST